Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen. This is an extension study to 1014802-203.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has completed Study 1014802-203 for its complete duration.
You may not be if
Has met an exclusion criterion for the preceding double-blind Phase 2b study (Study 1014802-203).
Had a treatment-related AE or SAE that would pose an increased risk for continued treatment with BIIB074, or discontinued study treatment in the double-blind Phase 2b study (Study 1014802-203) due to an AE or SAE.
Did not return for all study visits after discontinuing treatment in the double-blind phase of the Phase 2b study.
